PF-04620110

DRUG6 trials

Sponsors

Pfizer

Conditions

HealthyHealthy VolunteersObesityOverweightType 2 Diabetes Patients

Phase 1

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

CompletedNCT00799006

PfizerOverweight

Start: 2008-11-30End: 2009-06-30Updated: 2009-07-20

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

CompletedNCT00959426

PfizerHealthy, Obesity, Overweight

Start: 2009-08-31End: 2010-05-31Updated: 2010-06-07

A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects

CompletedNCT01064492

PfizerHealthy Volunteers

Start: 2010-02-28End: 2010-03-31Updated: 2010-03-18

A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects

CompletedNCT01146327

Start: 2010-06-30End: 2011-01-31Target: 60Updated: 2011-04-19

A Single Dose Study Of PF-04620110 In Healthy Subjects

CompletedNCT01166217

Start: 2010-07-31End: 2010-08-31Updated: 2010-08-20

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

CompletedNCT01298518

PfizerType 2 Diabetes Patients

Start: 2011-02-28End: 2011-05-31Updated: 2012-11-06

Related Papers

Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.

2023-01-2129 citations